This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia

This study has been completed.
Information provided by:
Genta Incorporated Identifier:
First received: August 3, 2001
Last updated: November 10, 2009
Last verified: November 2009
This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.

Condition Intervention Phase
Chronic Lymphocytic Leukemia CLL Drug: Oblimerson sodium, G3139 Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I-II Multicenter Study of Genasense (Bcl-2 Antisense Oligonucleotide) in Patients With Advanced Chronic Lymphocytic Leukemia

Resource links provided by NLM:

Further study details as provided by Genta Incorporated:

Enrollment: 40
Study Start Date: January 2001
Primary Completion Date: January 2003 (Final data collection date for primary outcome measure)
Detailed Description:

This study is a two-part phase I-II study. Part 1 will determine the MTD of Genasense in patients with CLL. This dose will then be tested in a non-randomized, multi-center, Phase II sequential clinical trial of Genasense used alone for treatment of patients with advanced CLL.

Pharmacokinetics of Genasense and kinetics of Bcl-2 down regulation and re-expression in CLL cells will be followed in selected patients.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Any age
  • Must have received at least one chemotherapy regimen that included fludarabine
  • Measurable disease
  • At least 3 weeks since biological therapy or radiation therapy for chronic lymphocytic leukemia
  • No previous stem cell transplantation
  • At least 3 weeks since surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00021749

United States, New York
Long Island Jewish Medical Center
New Hyde Park, New York, United States
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States
San Antonio Cancer Institute
San Antonio, Texas, United States
Sponsors and Collaborators
Genta Incorporated
  More Information

Publications: Identifier: NCT00021749     History of Changes
Obsolete Identifiers: NCT00021190
Other Study ID Numbers: GL208
Bcl-2 Antisense
Study First Received: August 3, 2001
Last Updated: November 10, 2009

Keywords provided by Genta Incorporated:

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell processed this record on August 21, 2017